WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline
WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million (1) in revenue and $22 million (1) in Adjusted EBITDA (2). WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR (3) of approximately $80 million, supported by robust organic expansion, continued adoption of its AI-powered tools, and inclusive of completing three acquisitions that are currently in signed LOI stage.
Amir Javidan, CEO of WELLSTAR commented, 'We've had an excellent first half to 2025 as both our organic and inorganic growth engines are levelling up and are poised to deliver an outstanding, breakout performance for WELLSTAR in 2025. At the beginning of the year, we set an ambitious goal of reaching $100M in revenues on a run-rate basis in the next couple of years and based on the latest forecasts, we believe we may be approaching that goal a few quarters earlier than previously anticipated. Our current goal for year-end exit ARR for fiscal 2025 is $80 million which would represent a 50% increase over last year's exit ARR figure.
Darren Hoegler, CFO of WELLSTAR commented, 'This upward revision reflects stronger-than-expected traction across WELLSTAR's core product suite as well as strong execution in the company's capital allocation program. We currently have three signed LOIs with targets that all deliver high-margin SaaS solutions and would be highly accretive to our business. I'm also pleased to report that the two acquisitions that were completed in Q4 2024 are both operating well and tracking in alignment with or ahead of our plan. Our objective is to ensure disciplined execution and that the company continues to be positioned as a category leader in Canadian digital health, delivering durable, capital-efficient growth with significant operating leverage over time.'
Three LOIs Executed as WELLSTAR Executes on Deep Acquisition Pipeline
WELLSTAR has executed three letters of intent (LOIs) for acquisitions that are expected to contribute approximately $15 million in ARR, $16 million in revenue, and over $5 million in Adjusted EBITDA on an annualized run-rate basis. These prospective additions reflect WELLSTAR's continued focus on disciplined, accretive growth through the acquisition of complementary digital health assets that strengthen its core platform and expand its national footprint.
The acquisitions are aligned with WELLSTAR's long-term strategy to build a technology-enabled healthcare infrastructure that is efficient, scalable, and outcomes-driven. Each target adds strategic value by extending WELLSTAR's clinician enablement capabilities. The integrated nature of WELLSTAR's platform enables smooth onboarding and operational alignment, allowing new assets to benefit from shared infrastructure and drive incremental impact across the broader business.
WELLSTAR continues to advance a deep and well-qualified acquisition pipeline, with additional opportunities under review.
Strong Early Traction for Nexus AI with Clinicians Nationwide
Since its launch on May 7, 2025, Nexus AI has seen strong adoption, with over 2,400 providers signed up across primary care clinics, hospitals, and regional health authorities. Nexus AI's first feature, an ambient medical scribe for real-time clinical documentation, is already demonstrating meaningful value for providers by reducing administrative burden and cognitive load. AI medical scribe technology has been shown to save providers up to two hours per day in charting and documentation (4).
Nexus AI serves as the central platform for WELLSTAR's expanding suite of AI-powered capabilities, including disease detection, medical coding and billing automation, and clinical decision support. Its compatibility with Canada's leading EMRs positions it as a scalable infrastructure layer for modern, intelligent healthcare delivery.
Clinician engagement with Nexus AI is expected to contribute to WELLSTAR's recurring SaaS revenue and margin profile as deployments scale. Just as importantly, the platform's ability to orchestrate complex clinical workflows in an intuitive and context-aware way supports broader system-level efficiency and provider satisfaction.
As a pre-qualified vendor of the Canada Health Infoway AI Scribe Program, eligible primary care clinicians across Canada will receive a fully-funded license for 12 months of Nexus AI. WELLSTAR recognizes this as a transformative opportunity to advance Canada's vision of connected care, where AI-enabled technologies reduce physician burnout, improve patient experience, and allow providers to focus more on engagement and less on documentation. By delivering accurate, secure documentation at the point of care, Nexus AI empowers providers to reclaim meaningful patient connections and supports a broader effort to integrate AI technologies that promote more connected, patient-centred care.
Footnotes:
WELLSTAR's guidance of $74 million in revenue and $22 million in Adjusted EBITDA in fiscal 2025 includes the impact from the three LOIs noted herein which will contribute approximately $4 million in revenue and $1 million in Adjusted EBITDA for inclusion in fiscal 2025. Note that this figure does not include certain shared services that are provided by WELL Health to WELLSTAR.
Adjusted EBITDA is a non-GAAP financial measure. Please refer to WELL's most recent Management's Discussion and Analysis (MD&A), available under the Company's profile on SEDAR+ at www.sedarplus.ca, for further details including definitions and reconciliations to the nearest IFRS measure.
Exit ARR or Annual Recurring Revenue is based on the Company's revenue run-rate or ARR as annualized based on the last quarter of the year. The projected Exit ARR of approximately $80 million includes contribution from the three LOIs noted herein.
Source: OntarioMD, AI scribes show promising results in helping family doctors and nurse practitioners spend more time with patients and less time on paperwork, September 11, 2024. https://www.ontariomd.ca/pages/ai-scribes-promising-results.aspx
WELL HEALTH TECHNOLOGIES CORP.
Per: 'Hamed Shahbazi'
Chief Executive Officer, Chairman and Director
WELL Health Technologies Inc.
WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: www.well.company.
Forward-Looking Statements
Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the guidance related to revenue and adjusted EBITDA, and the expected pipeline of future acquisition targets (and the associated run-rate revenue). Forward-looking statements are necessarily based upon management's expectations, while considered reasonable by WELL as of the date of such statements, are outside of WELL's control and are inherently subject to business, economic and other uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to continue to offer its products and services, complete the acquisitions, and the acquisition companies having the expected revenue and Adjusted EBITDA profiles based on WELL's diligence.
Known and unknown risk factors, many of which are beyond the control of WELL could cause the actual plans to differ materially from the results implied by such forward-looking statements. Such risk factors include losing customers to competitors, cybersecurity threats which prevent WELLSTAR from being able to continually offer its products, not completing the three acquisitions discussed above, and the other risks discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form, which is available under the Company's respective SEDAR+ profile at www.sedarplus.ca which could affect WELL's and WELLSTAR's business. The risk factors are not intended to represent a complete list of the factors that could affect WELL or WELLSTAR and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Up Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher?
Tilray's stock has been rallying since the start of July despite an absence of significant news. Investors have often bought the stock on hopes that the U.S. marijuana market will open up. However, that doesn't appear to be on the horizon, and Tilray faces many challenges ahead. 10 stocks we like better than Tilray Brands › The S&P 500 index has been hitting record highs and may be running out of room to rise a whole lot more. For investors, now may be an opportune time to pay attention to stocks which may be poised for greater gains and which haven't been doing particularly well. One notable stock of late has been Tilray Brands (NASDAQ: TLRY), which has a diverse business centering around cannabis and beverages. While it hasn't been a strong buy at all this year (it's down more than 50% year to date), it has been picking up steam of late. As of Friday, it was up around 40% in the past month. Could this struggling stock be on track for an even bigger rally ahead, or could this be just a short-lived bump-up in value? The big reason to invest into Tilray is if you're bullish on marijuana legalization in the U.S. If that happens, the Canadian-based cannabis producer would have a way to enter a huge, lucrative market, enabling it to drastically grow its sales. But with nothing seemingly happening on that front of late, growth investors have, for the most part, avoided it. As of the end of June, the stock was down a whopping 69% as it looked poised for yet another disastrous year. In 2024, the pot stock fell by more than 40% after declining by nearly 15% the year before that. But in the first few days of July, Tilray's stock started to rally. And on July 9 it hit an intra-day high of $0.70 -- levels it hadn't hit since March. The company, however, hasn't released any major news of late, and its latest quarterly report isn't coming out until later this month, on July 28. Investors buying Tilray may simply have been pivoting to cheaper stocks, especially with the markets up around record levels and many top-performing stocks looking expensive. Tilray is also a popular stock with retail investors, and when its momentum picks up, for any reason, that can lead to a snowball effect. The problem with Tilray is that it's struggling to find ways to grow its business in a sustainable way. It's leaned on acquisitions of craft brewers in the past as a way to expand its operations. But acquisitions often lead to just temporary, short-term boosts. Tilray's sales growth rate has been underwhelming of late. For the period ended Feb. 28, its net revenue totaled $186 million and was down more than 1% year over year. Without a U.S. cannabis market to tap into right now, and the company incurring a net loss of more than $913 million over the past three quarters, there isn't an overwhelming reason for investors to want to take a chance on the stock, even if it may look cheap. Tilray's stock got a boost recently despite no significant developments. That's a sign of just how dangerously speculative and unpredictable the stock can be. While it may be tempting to buy into a stock that's suddenly taking off, this type of rally usually doesn't end up being sustainable. Consider that over the past five years, shares of Tilray have fallen an incredible 93%. Although there may be brief spikes along the way, it's been an incredibly strong, downward trend for the stock. And without a reason to expect that things will get better for Tilray anytime soon, investors may still be better off steering clear of this highly risky and volatile stock. Before you buy stock in Tilray Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tilray Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you'd have $680,559!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,670!* Now, it's worth notingStock Advisor's total average return is1,053% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. Up Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher? was originally published by The Motley Fool
Business Wire
9 minutes ago
- Business Wire
Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. Cardiovascular disease continues to be a critical public health issue in the United States, remaining the leading cause of death nationwide. In 2022, heart disease claimed over 700,000 lives—nearly 1 in every 5 deaths—underscoring the urgent need for early detection and intervention. 1 Despite advances, many high‑risk patients remain undiagnosed until they experience serious cardiac events. The proposed rule by CMS marks a significant step toward broader access to innovative, evidence-based imaging tools that help identify high-risk cardiovascular patients earlier and more accurately. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. 'We commend CMS for ensuring that the proposed payment level reflects the clinical value, technological investment, and expertise needed to perform this service, enabling Medicare beneficiaries to access this technology.' Coronary computed tomography angiography (CTA) with plaque analysis offers invaluable insights into plaque burden, composition, and morphology, enabling earlier and more accurate identification of high-risk patients who may benefit from targeted medical therapy and lifestyle interventions. Numerous studies have demonstrated that such non-invasive imaging enhances risk stratification and clinical decision-making while reducing the need for more invasive and costly diagnostic procedures. 'Elucid remains optimistic as we await the final publication of the code and payment, effective January 1, 2026,' said Huang. 'We recognize the efforts of societies and physician organizations collaborating with the AMA and CMS to reach an appropriate payment level. We look forward to continued cooperation to enhance patient outcomes and access.' The proposed rule outlines payment policies and rates for services furnished under Medicare Part B. The inclusion of coronary CTA with plaque analysis represents a significant advancement for precision cardiovascular care. It follows a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357. This has already allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Hamilton Spectator
12 minutes ago
- Hamilton Spectator
New trade deal with the U.S. likely to include tariffs, Mark Carney says
OTTAWA—A trade deal with the United States is unlikely without some level of tariffs, Prime Minister Mark Carney said Tuesday. 'There's not a lot of evidence right now that agreements, negotiations with the Americans, for any country or any jurisdiction to have an agreement without tariffs,' he told reporters in French ahead of a cabinet meeting to discuss trade negotiations. His comments came a day after U.S. President Donald Trump declared that the letters he sent to Carney and other world leaders about new tariff rates are 'the deals.' 'The deals are made. There are no deals to make,' Trump said during an Oval Office meeting with NATO Secretary-General Mark Rutte. 'They would like to do a different kind of a deal and we are always open to talking.' In the letter sent to Canada Thursday night, Trump threatened to unilaterally impose a 35-per-cent tariff on imports from Canada by Aug. 1, pushing back a deal deadline previously set for July 21. A White House official later suggested that the new tariff would only apply to goods that already face a 25 per cent tariff, which would exempt many goods that comply with the Canada-U.S.-Mexico Agreement, although they indicated no decision was final. On Tuesday, Carney said his goal is to 'stabilize' the situation for Canada, describing the current tariff situation as 'almost free trade' between the neighbouring countries. Previously, Trump's envoy to Canada told the Star that American officials have asserted in negotiations that some level of tariffs on Canadian products is the new normal . Carney will also be convening an emergency first ministers' meeting in Huntsville before the start of the annual premiers' gathering on July 22.
